<DOC>
	<DOCNO>NCT01850004</DOCNO>
	<brief_summary>The study purpose test hypothesis Chronic Phase Chronic Myeloid Leukemia ( CP-CML ) patient stable Complete Molecular Response ( CMR ) discontinue Dasatinib treatment able maintain sustain remission long-term , undetectable minimally detectable BCR-ABL residual disease .</brief_summary>
	<brief_title>Open-Label Study Evaluating Dasatinib Therapy Discontinuation Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response</brief_title>
	<detailed_description>Primary Purpose : Protocol design evaluate remission disease treatment discontinuation . Treatment re-started relapse occurs</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Signed Written Informed Consent Target Population 1 . Men woman diagnose CPCML , treatment dasatinib minimum 2 year time enrollment dasatinibinduced complete molecular remission ongoing least 1 year prior study entry . 2 . Patients eligible stable dasatinib induce CMR minimum nine month , document least three assessment , conduct 2 6.5 month apart , local lab . 3 . Subjects receive dasatinib beyond first second line treatment meet enrollment criterion eligible study provide prior Tyrosinekinase inhibitor ( TKI ) discontinue due intolerance lack efficacy , although one instance lack efficacy TKI allow . 4 . Eastern CoOperative Group ( ECOG ) Performance Status ( PS ) 01 Age Reproductive Status 1 . Men woman , age ≥18 2 . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 24 hour prior restart study drug 3 . Women must breastfeed 4 . WOCBP must agree follow instruction method ( ) contraception restart treatment study drug ( dasatinib ) duration treatment plus 30 day ( duration ovulatory cycle ) total 30 day posttreatment completion 5 . Men sexually active WOCBP must agree follow instruction method ( ) contraception 90 day study entry ( withdrawal dasatinib ) , restart study drug ( dasatinib ) duration treatment study drug ( dasatinib ) plus 90 day ( duration sperm turnover ) total 90 day posttreatment completion Target Disease Exceptions 1 . Patients achieve 1log reduction BCRABL transcript level compare baseline determine local standard &gt; 10 % IS [ International Standard ] ) document 3.06.5 month since initial start dasatinib therapy . 2 . Patients previously undergone hematopoietic stem cell transplantation ( SCT ) schedule SCT 3 . Previous diagnosis CML accelerate phase blast crisis Medical History Concurrent Diseases 1 . Prior concurrent malignancy , except follow : Curatively treat basal cell squamous cell skin cancer Cervical carcinoma situ Adequately treat Stage I II cancer subject currently complete remission Any cancer subject disease free 3 year 2 . A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy case reinitiation dasatinib need . 3 . Uncontrolled significant cardiovascular disease 4 . Subjects prior history pericardial effusion pleural effusion require thoracentesis exclude . Subjects prior history pericardial pleural effusion clinically manageable maintain CMR ≥ 1 year stable dose dasatinib allow . 5 . History significant bleeding disorder unrelated CML Allergies Adverse Drug Reaction . Subjects know hypersensitivity excipients Dasatinib tablet Sex Reproductive Status 1 . Patients pregnant breastfeed likely become pregnant 2 . Men whose partner unwilling unable avoid pregnancy Other Exclusion Criteria 1 . Patients history noncompliance CML treatment monitoring requirement 2 . Prisoners subject involuntarily incarcerate Additional Criteria Patients Eligible Restart Dasatinib Any patient lose MMR eligible restart dasatinib therapy must develop condition precludes dasatinib use . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>